MEDICINES CO /DE filed this form 10-Q on 15 May 2002
<PAGE> 3 1.8. "Intellectual Property Rights" shall mean know how, patents, trade marks, service marks, trade names, registered designs, design rights, copyright (including rights in computer software) and any rights or property similar to any of the foregoing in any part of the world whether registered or not registered together with the right to apply for the registration of any such rights. 1.9. "License Agreement" shall mean the License Agreement providing for an exclusive license to the Product (as therein defined) by and between the Parties, attached hereto as a Schedule 2. 1.10. "License Agreement Effective Date" shall have the meaning defined in Article 9.1.3. 1.11. "License Agreement Notice" shall have the meaning defined in Article 9.1.1. 1.12. "Party" or "Parties" shall mean TMC and/or ASTRAZENECA. 1.13. "Person" shall mean an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organisation, including a government or political subdivision, department or agency of a government. 1.14. "Pilot Study" shall mean the clinical study to be carried out according to the study outline attached hereto as a Schedule 3. 1.15. "Product" shall mean any pharmaceutical formulation or product for intravenous application containing the Compound as the sole active ingredient in a finished dosage form suitable for administration to patients. 1.16. "Results" shall mean any inventions, formulae, products, processes, techniques, discoveries, improvements, information, data and knowledge developed, generated or reduced to practice under or in connection with the Pilot Study and any Intellectual Property Rights related thereto.